HK1099286A1 - 5,7-diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity - Google Patents

5,7-diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity

Info

Publication number
HK1099286A1
HK1099286A1 HK07105414.0A HK07105414A HK1099286A1 HK 1099286 A1 HK1099286 A1 HK 1099286A1 HK 07105414 A HK07105414 A HK 07105414A HK 1099286 A1 HK1099286 A1 HK 1099286A1
Authority
HK
Hong Kong
Prior art keywords
diaminopyrazolo
pde
pyrimidines
inhibiting activity
inhibiting
Prior art date
Application number
HK07105414.0A
Other languages
English (en)
Inventor
Andrew Simon Bell
David Graham Brown
Kevin Neil Dack
David Nathan Abraham Fox
Ian Roger Marsh
Andrew Ian Morrell
Michael John Palmer
Carol Ann Winslow
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HK1099286A1 publication Critical patent/HK1099286A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK07105414.0A 2003-11-24 2007-05-22 5,7-diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity HK1099286A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0327319.0A GB0327319D0 (en) 2003-11-24 2003-11-24 Novel pharmaceuticals
PCT/IB2004/003747 WO2005049616A1 (en) 2003-11-24 2004-11-12 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY

Publications (1)

Publication Number Publication Date
HK1099286A1 true HK1099286A1 (en) 2007-08-10

Family

ID=29764364

Family Applications (2)

Application Number Title Priority Date Filing Date
HK07105414.0A HK1099286A1 (en) 2003-11-24 2007-05-22 5,7-diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity
HK09107080.7A HK1128917A1 (en) 2003-11-24 2009-08-03 5,7-diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK09107080.7A HK1128917A1 (en) 2003-11-24 2009-08-03 5,7-diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity

Country Status (44)

Country Link
EP (1) EP1689751B1 (hr)
JP (1) JP4056015B2 (hr)
KR (2) KR100893999B1 (hr)
CN (4) CN101362764B (hr)
AP (1) AP2227A (hr)
AR (1) AR046711A1 (hr)
AT (1) ATE485297T1 (hr)
AU (1) AU2004290643B2 (hr)
BR (1) BRPI0416869A (hr)
CA (1) CA2546987C (hr)
CR (1) CR8416A (hr)
CY (1) CY1110933T1 (hr)
DE (1) DE602004029705D1 (hr)
DK (1) DK1689751T3 (hr)
EA (1) EA011772B1 (hr)
EC (1) ECSP066580A (hr)
ES (1) ES2351622T3 (hr)
GB (1) GB0327319D0 (hr)
GE (1) GEP20084528B (hr)
HK (2) HK1099286A1 (hr)
HR (1) HRP20100651T1 (hr)
IL (1) IL175433A (hr)
IS (1) IS8406A (hr)
MA (1) MA28172A1 (hr)
ME (1) ME01216B (hr)
MX (1) MXPA06005914A (hr)
MY (1) MY140872A (hr)
NL (1) NL1027568C2 (hr)
NO (1) NO336526B1 (hr)
NZ (1) NZ548097A (hr)
OA (1) OA13289A (hr)
PA (1) PA8617701A1 (hr)
PE (1) PE20051061A1 (hr)
PL (1) PL1689751T3 (hr)
PT (1) PT1689751E (hr)
RS (1) RS51556B (hr)
SG (1) SG133614A1 (hr)
SI (1) SI1689751T1 (hr)
TN (1) TNSN06154A1 (hr)
TW (1) TWI265031B (hr)
UA (1) UA81994C2 (hr)
UY (1) UY28625A1 (hr)
WO (1) WO2005049616A1 (hr)
ZA (1) ZA200602899B (hr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1799668A1 (en) 2004-09-20 2007-06-27 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
CA2580787A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
BRPI0515488A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados de heterocìclicos e seu uso como agentes terapêuticos
US7592343B2 (en) 2004-09-20 2009-09-22 Xenon Pharmaceuticals Inc. Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
WO2006034341A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
WO2006046135A2 (en) * 2004-10-28 2006-05-04 Pharmacia & Upjohn Company Llc Pyrazolo[4,3-d] pyrimidine derivatives useful as pde-5 inhibitors
BRPI0609225A2 (pt) 2005-05-12 2010-03-09 Pfizer formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
NL1029244C2 (nl) * 2005-06-10 2006-12-12 Ronald Silfried Marlin Middel ter vergroting van het mannelijk geslachtsorgaan.
DE102005050377A1 (de) * 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
NL2000291C2 (nl) * 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
ES2562428T3 (es) 2005-12-15 2016-03-04 Rigel Pharmaceuticals, Inc. Inhibidores de cinasa y sus usos
EP1820502A1 (en) * 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
WO2007113243A2 (en) * 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
WO2008132589A1 (en) * 2007-05-01 2008-11-06 Pfizer Limited Combinations comprising pregabalin
WO2009050554A2 (en) * 2007-10-19 2009-04-23 Pfizer Inc. Treatment of central nervous system disorders
DE102008063992A1 (de) * 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
CA2830027C (en) 2011-03-31 2016-04-26 Pfizer Inc. Novel bicyclic pyridinones
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
ES2605565T3 (es) 2011-08-31 2017-03-15 Pfizer Inc Compuestos de hexahidropirano [3,4-D][1,3]tiazin-2-amina
WO2013164730A1 (en) 2012-05-04 2013-11-07 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2.
CA2882389A1 (en) 2012-09-20 2014-03-27 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014091352A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
EP2935282A1 (en) 2012-12-19 2015-10-28 Pfizer Inc. CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
EP2956458B1 (en) 2013-02-13 2017-08-09 Pfizer Inc Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
KR20150119370A (ko) 2013-02-19 2015-10-23 화이자 인코포레이티드 Cns 장애 및 다른 장애의 치료를 위한 pde4 동종효소의 억제제로서의 아자벤즈이미다졸 화합물
CA2925743C (en) 2013-10-04 2018-03-06 Pfizer Inc. Novel bicyclic pyridinones as gamma-secretase modulators
JP2017500333A (ja) * 2013-12-20 2017-01-05 バイエル・ファルマ・アクティエンゲゼルシャフト グルコース輸送阻害剤
EA031419B1 (ru) 2014-04-01 2018-12-28 Пфайзер Инк. ХРОМЕН И 1,1a,2,7b-ТЕТРАГИДРОЦИКЛОПРОПА[c]ХРОМЕН ПИРИДОПИРАЗИНДИОНЫ В КАЧЕСТВЕ МОДУЛЯТОРА ГАММА-СЕКРЕТАЗЫ
PL3126354T3 (pl) * 2014-04-04 2020-06-15 H. Lundbeck A/S Fluorowcowane chinazolino-THF-aminy jako inhibitory PDE1
CA2944971C (en) 2014-04-10 2019-05-07 Pfizer Inc. 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yl amides
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
BR112017001334A2 (pt) 2014-08-06 2017-11-14 Pfizer compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende
US9981976B2 (en) * 2014-12-08 2018-05-29 Janssen Sciences Ireland Uc Piperidine substituted pyrazolo[1,5-A]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV)
CN107406445B (zh) 2015-02-03 2019-12-24 辉瑞公司 新颖环丙苯并呋喃基吡啶并吡嗪二酮类
PT3766885T (pt) 2015-06-17 2022-08-09 Pfizer Compostos tricíclicos e a sua utilização como inibidores de fosfodiesterase
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
WO2017051294A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
BR112018003489A2 (pt) 2015-09-24 2018-09-25 Pfizer n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas
PL3419979T3 (pl) 2016-02-23 2020-06-29 Pfizer Inc. Związki 6,7-dihydro-5h-pirazolo[5,1-b][1,3]oksazyno-2- karboksyamidowe
AU2017286868B2 (en) 2016-07-01 2021-11-11 Pfizer Inc. 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
KR20200013783A (ko) 2017-06-22 2020-02-07 화이자 인코포레이티드 디히드로-피롤로-피리딘 유도체
TWI801540B (zh) 2018-03-23 2023-05-11 美商輝瑞大藥廠 哌嗪氮雜螺衍生物
KR20210033444A (ko) 2018-06-04 2021-03-26 엑스사이언티아 엘티디 아데노신 수용체 길항제로서 피라졸로피리미딘 화합물
MA53448A (fr) * 2018-08-24 2022-04-20 Terns Inc Composés agonistes des récepteurs bêta des hormones thyroïdiennes
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
GB9823102D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
CA2347950C (en) * 1998-10-23 2005-05-03 Pfizer Inc. Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
DE10031236A1 (de) * 2000-06-27 2002-01-10 Qiagen Gmbh Verwendung von Carbonsäuren und anderen Additiven in Kombination mit kationischen Verbindungen zur Stabilisierung von Nukleinsäuren in biologischen Materialien
DE10031584A1 (de) * 2000-06-29 2002-01-10 Merck Patent Gmbh 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
DK1348707T3 (da) * 2002-03-28 2010-12-13 Ustav Ex Botan Av Cr V V I Inst Of Ex Botany Academy Of Sciences Of The Czech Republic Pro Pyrazolo[4,3-d]pyrimidiner, fremgangsmåder til deres fremstilling samt deres terapeutiske anvendelse
OA13050A (en) * 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.

Also Published As

Publication number Publication date
NZ548097A (en) 2008-12-24
TW200520758A (en) 2005-07-01
NL1027568A1 (nl) 2005-05-26
ECSP066580A (es) 2006-12-20
SI1689751T1 (sl) 2011-01-31
EA200600677A1 (ru) 2006-12-29
ATE485297T1 (de) 2010-11-15
AR046711A1 (es) 2005-12-21
ZA200602899B (en) 2007-07-25
OA13289A (en) 2007-01-31
UY28625A1 (es) 2005-06-30
CN101647802A (zh) 2010-02-17
AP2227A (en) 2011-03-29
AU2004290643B2 (en) 2008-08-07
KR100893999B1 (ko) 2009-04-20
DK1689751T3 (da) 2011-01-17
KR20070026334A (ko) 2007-03-08
KR100848216B1 (ko) 2008-07-24
MY140872A (en) 2010-01-29
HRP20100651T1 (hr) 2011-01-31
TNSN06154A1 (fr) 2007-11-15
CN101362765B (zh) 2011-02-02
SG133614A1 (en) 2007-07-30
ME01216B (me) 2013-03-20
CN101362765A (zh) 2009-02-11
ES2351622T3 (es) 2011-02-08
PT1689751E (pt) 2010-11-29
NO336526B1 (no) 2015-09-21
GEP20084528B (en) 2008-11-10
AP2006003591A0 (en) 2006-04-30
CA2546987A1 (en) 2005-06-02
CN101362764A (zh) 2009-02-11
EP1689751B1 (en) 2010-10-20
NO20062950L (no) 2006-08-23
NL1027568C2 (nl) 2005-11-30
MA28172A1 (fr) 2006-09-01
PE20051061A1 (es) 2005-12-12
EP1689751A1 (en) 2006-08-16
IL175433A0 (en) 2006-09-05
CY1110933T1 (el) 2015-06-10
MXPA06005914A (es) 2006-06-27
CN1882591B (zh) 2011-08-10
IS8406A (is) 2006-04-10
CA2546987C (en) 2009-05-12
RS51556B (en) 2011-06-30
JP2007512314A (ja) 2007-05-17
WO2005049616A1 (en) 2005-06-02
JP4056015B2 (ja) 2008-03-05
TWI265031B (en) 2006-11-01
KR20080052666A (ko) 2008-06-11
PL1689751T3 (pl) 2011-03-31
IL175433A (en) 2011-08-31
PA8617701A1 (es) 2005-08-04
AU2004290643A1 (en) 2005-06-02
CN101362764B (zh) 2011-04-20
CR8416A (es) 2006-11-15
CN1882591A (zh) 2006-12-20
WO2005049616A8 (en) 2006-06-01
BRPI0416869A (pt) 2007-03-27
DE602004029705D1 (de) 2010-12-02
UA81994C2 (en) 2008-02-25
GB0327319D0 (en) 2003-12-24
HK1128917A1 (en) 2009-11-13
EA011772B1 (ru) 2009-06-30

Similar Documents

Publication Publication Date Title
HK1099286A1 (en) 5,7-diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity
IL182099A0 (en) Piperidinylamino-thieno[2,3-d] pyrimidine compounds
EP1599482A4 (en) PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES
PL376916A1 (pl) Pochodne pirymido [4,5-d] pirymidyny o działaniu przeciwrakowym
IL170680A0 (en) 8 - SUBSTITUTED - 6,7,8,9 -TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
TWI365189B (en) Novel pyrrolo[3,2-d]pyrimidin-4-one derivatives
EG24843A (en) Herbicidal pyrimidines
HK1088893A1 (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives
EP1653969A4 (en) PYRROLO 1,2-B PYRIDAZINE DERIVATIVES
HK1091488A1 (en) Pyrimidine derivatives
ZA200604960B (en) Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-A]pyrimidin-6-onederivatives
AP2002002543A0 (en) Pyrrolo Ä2,3-dÜ pyrimidine compounds
IL172098A0 (en) Triazolopyrimidines
IL172848A0 (en) 2-substituted pyrimidines
ZA200510276B (en) Triazolopyrimidines
PL358551A1 (en) 5-aminoalkyl-pyrazolo[4,3-d]pyrimidines
PL372989A1 (en) Triazolopyrimidines
MXPA03004498A (es) Uso de pirazolo (4,3-d)pirimidinas.
IL172845A0 (en) 2-substituted pyrimidines
TWI372760B (en) A pyrazolo[1,5-a]pyrimidine compound
MXPA03004907A (es) Uso de pirazolo (4,3-d) pirimidinas.
GB0323137D0 (en) 2,4,6- Trisubstituted pyrimidines and their different uses
IL173347A0 (en) 7-SUBSTITUTED 3-NITRO-PYRAZOLO[1,5-a] PYRIMIDINES
TJ431B (en) 2-Brom-7-methil-5-oxo-5h-1,3,4-thyodyazol-(3,2-a)pyrimidin, has antibacterial activity
SI1567522T1 (sl) Pirimidinske spojine

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181112